Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial

Conclusions Once-daily solifenacin oral suspension in children with OAB was superior to placebo for MVV (primary efficacy endpoint) and was well tolerated. Patient summary In this 12-wk study, a once-daily oral suspension of solifenacin in children aged 5–<12 yr with overactive bladder was superior to placebo in increasing mean volume voided/micturition, the primary efficacy variable in the study. Solifenacin was well tolerated, with a low incidence of dry mouth and constipation. This study is registered at ClinicalTrials.gov as NCT01565707. A once-daily oral suspension of solifenacin in children aged 5–<12 yr with overactive bladder was superior to placebo for the primary efficacy endpoint of mean volume voided/micturition. Solifenacin was well tolerated, with low incidence of dry mouth and constipation.
Source: European Urology - Category: Urology & Nephrology Source Type: research